Syntara Limited · ASX:SNT
Syntara — Q1 2024 Earnings Presentation
10 slides from Syntara's earnings presentation, Apr 30, 2024
Slide 1: Quarterly Shareholder Update: March 2024
For personal use only ™ Quarterly Shareholder Update: March 2024 Gary Phillips, CEO 30th April 2024
Slide 2: Forward looking statement
Forward looking statement For personal use only This document contains involve known and unknown forward-looking statements, risks, uncertainties and other including statements factors, many of which are concerning Syntara’s future beyond our control, and which financial position, plans, and may cau
Slide 3: Highlights from March Quarter 2024
Highlights from March Quarter 2024 • Myelofibrosis phase 2 study recruiting on schedule For personal use only • 19 trial sites in Australia, Korea, Taiwan and US • 60% recruited as at end of April 2024 • On track to complete recruitment by mid 2024 • Interim data at American Society of Hematology De
Slide 4: Myelofibrosis
Myelofibrosis A rare type of bone marrow cancer that disrupts the body's normal production of blood cells For personal use only Key Facts Primary Myelofibrosis is Current standard SNT-5505 characterised by a build up of scar of care (SoC): JAK inhibition In contrast to SoC tissue (fibrosis) in bone
Slide 5: SNT-5505 Phase 2a trial (INTERIM results)
SNT-5505 Phase 2a trial (INTERIM results) Demonstrates improvements in fibrosis grade, excellent safety profile and promising signs of clinical activity For personal use only Study status Efficacy • 100% of target (24 pts) enrolled • 5/ 10 evaluable patients* had improved bone • 11 patients having c
Slide 6: Phase 2a study; SNT-5505 in patients on a stable dose of JAK inhibitor
Phase 2a study; SNT-5505 in patients on a stable dose of JAK inhibitor Study Plan For personal use only Fastest route to meaningful data with no dose escalation and utilizing existing trial infrastructure • 19 clinical trial sites • Recruitment Study Treatment started 13 Dec Design Endpoints Populat
Slide 7: Potential to deliver near term value
Potential to deliver near term value Pipeline creates multiple opportunities in high value markets For personal use only Addressable market Drug Candidate Indication Phase Upcoming Milestones (US$) Interim 6 month data Myelofibrosis (MF) Phase 2 ~$1 billion1 Q4 2024 SNT-5505 Myelodysplastic Syndrome
Slide 8: Shareholders & cash
Shareholders & cash Financial Information (ASX: SNT) 28 April 24 Share Price & Volume For personal use only Share price $0.017 0.07 Market Cap A$20m 0.06 Cash balance (31 March 2024)1 A$7m 0.05 Enterprise value A$13m Note: 0.04 1. Additional funds expected from acquiror of MBU (~$6m) and returned se
Slide 9: Recent & upcoming news flow
Recent & upcoming news flow Strong and growing pipeline with advancement in studies expected to provide value inflection points For personal use only COMPLETED COMPLETED COMPLETED Q2 2024 Mid 2024 Q4 2023 Q4 2023 Q4 2023 SNT-4728 iRBD / SNT-5505 phase 2a SNT-5505 phase 2a Pan-LOX scar SNT-5505 phase
Slide 10: For personal use only
For personal use only Gary Phillips Syntara Limited ABN 75 082 811 630 Chief Executive Officer gary.phillips@syntaraTX.com.au David McGarvey Chief Financial Officer david.mcgarvey@syntaraTX.com.au www.syntaraTX.com.au